Will A Virtual JPM Result In Less Sense Of Urgency Or Changes In Pitching

Three biopharma executives discuss how a virtual JPM will impact the traditional sense of urgency around the conference, approaches to pitching, thoughts on operating at JPM post pandemic, along with some parting pearls of wisdom. This is part of a larger executive virtual roundtable (EVR) conducted by Rob Wright, chief editor of Life Science Leader, that included Terry-Ann Burrell, CFO, Beam Therapeutics; Hunter Smith, CFO, Rhythm Pharmaceuticals; and Jim Woody, Ph.D., CEO, 180 Life Sciences (view full video here). The topic for this EVR is the 39th Annual J.P. Morgan Healthcare Conference being 100% virtual in 2021, and how that’s impacting preparations.